Aligos Therapeutics, Inc. Common Stock (ALGS) Stock Price, Quote & AI Analysis

Live ALGS stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Aligos Therapeutics, Inc. Common Stock.

TradeVae provides AI-driven analysis and real-time market intelligence for Aligos Therapeutics, Inc. Common Stock (ALGS), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.

ALGS
Aligos Therapeutics, Inc. Common Stock
real-time
$0.00 +0.00 (+0.00%)
Open
7.980000
High
8.390000
Low
7.830000
Volume
56,769
VWAP
-
Market Cap
$49,659,406.74
52W Range
$3.76 - $29.54
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Upcoming Earnings
Mar 9, 2026 Q4
After Hours
EPS Estimate: $-1.609
Revenue Estimate: $816,000.00
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Aligos Therapeutics, Inc. Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Aligos Therapeutics, Inc. Common Stock Overview

Company information

Company Overview

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 5, 2018 and is headquartered in South San Francisco, CA.

Company Details
Market Cap
$50.12M
Shares Outstanding
6,153,582
Weighted Shares Outstanding
6,153,582
CEO
Lawrence M. Blatt
Address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080
Employees
70
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
XNAS

Technical Indicators

Key technical analysis metrics and signals

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Aligos Therapeutics, Inc. Common Stock Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...